Table 1.
Patient Demographic and Clinical Characteristics
| Parameter | Phase I (n=28) | Phase II (n=37) |
|---|---|---|
| Age, years | ||
| Median | 38 | 34 |
| Range | 25–70 | 18–72 |
| Sex | ||
| Male | 18 (64%) | 23 (62%) |
| Female | 10 (36%) | 14 (38%) |
| Ethnicity | ||
| White, non-Hispanic | 18 (64%) | 25 (68%) |
| White Hispanic | 0 (0%) | 1 (3%) |
| Black, non-Hispanic | 3 (11%) | 2 (5%) |
| Asian/Indian/Pacific Islander | 1 (4%) | 5 (14%) |
| Other | 6 (21%) | 4 (11%) |
| Disease | ||
| Hodgkin’s lymphoma | 27 (96%) | 37 (100%) |
| ALCL | 1 (4%) | 0 (0%) |
| Prior Therapy | ||
| Median: 4 (range: 1–12) | 5 (2–12) | 3 (1–8) |
| ABVD/BEACOPP/EVA | 27 (96%) | 37 (100%) |
| Platinum based (ICE/ESHAP/DHAP) | 28 (100%) | 29 (78%) |
| Autologous stem cell transplant | 21 (75%) | 21 (27%) |
| Allogeneic transplant | 2 (7%) | 1 (3%) |
| Radiotherapy | 12 (43%) | 17 (46%) |
| Alkylator based (Lomustine/MOPP) | 15 (54%) | 2 (5%) |
| Lenalidomide | 9 (32%) | 3 (8%) |
| Vinblastine | 10 (36%) | 2 (5%) |
| Gemcitabine based (GCD, Gem/Vin) | 9 (32%) | 1 (3%) |
| Brentuximab vedotin | 8 (29%) | 3 (8%) |
| HDAC inhibitor | 5 (18%) | 0 (0%) |
| Experimental drug1 | 4 (14%) | 3 (8%) |
| Etoposide | 2 (7%) | 0 (0%) |
1
Experimental drugs included: HCD122 Lucatumumab (n=3), NAE Inhibitor MLN4924 (n=1), TGR-1202 (n=1), Azacitidine/Romidepsin (n=1), ACY1215 (n=1).